Sustained suppression of fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells

Apoptosis

Volumn 4, Issue 4, 1999, Pages 271-282

  Schneiderman, D ^b   Kim, J M ^b   Senterman, M ^b   Tsang, B K ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

Apoptosis; Chemoresistance; Cisplatin; Fas; FasL; Ovarian cancer

Indexed keywords

CISPLATIN; FAS ANTIGEN; FAS LIGAND; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; EPITHELIUM CELL; FEMALE; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN CONTENT;

EID: 0032830794     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1026456926754     Document Type: Article

References (33)

1. Nyens B, Katesuwanasing H, Vermeij J, et al. Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Oncogene 1996; 12: 1247-1257.
2. Ormerod MG, O'Neill C, Robertson D, Kelland LR, Harrap KR. cis-Diamminedichloroplatinum (II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharm 1996; 37: 463-471.
3. Soldatenkov VA, Prasad S, Notario V, Dritschilo A. Radiation-induced apoptosis of Ewings's sarcoma cells: DNA fragmentation and proteolysis of poly (ADP-ribose) polymerase. Cancer Res 1995; 55: 4240-4242.
4. Havrilesky LJ, Elbedary A, Hurteau JA, Whitaker RS, Rodriquez GC, Berchuck A. Chemotherapy-induced apoptosis in epithelial ovarian cancer. Obstet Gyne 1995; 85: 1007-1010.
5. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R. Micorsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumour cells. Cancer Res 1996; 56: 1374-1387.
6. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990; 2: 35.
7. Stewart DJ, Raaphorst GP, Yau J, Beaubien AR. Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 1996; 14: 115-130.
8. Reed JC, Toshiyuki M, Takayama S, et al. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60: 23-32.
9. Sherman SE, Lippard SJ. Structural aspects of platinum anti-cancer drug interaction with DNA. Chem Rev 1987; 87: 1153-1157.
10. Sorenson CM, Barry MA, Eastman AJ. Analysis of events associated with cell cycle arrest at G2 phase and cell and cell death induced by cisplatin. J Natnl Cancer Inst 1990; 82: 749-755.
11. Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-562.
12. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-243.
13. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994; 179: 873-879.
14. Kim JM, Boone DL, Auyeung A, Tsang BKT. Granulosa cell apoptosis induced at the penultimate stage of follicular development is associated with increased levels of Fas and Fas ligand in the rat ovary. Biol of Reprod 1998; 58:1170-1176.
15. Wakahara Y, Nawa A, Okamoto T, et al. Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Oncology 1997; 54: 48-54.
16. Uslu R, Jewett A, Bonavida B. Sensitzation of human ovarian tumor cells by subtoxic CDDP to anti-Fas antibody-mediated cytotoxicity and apoptosis. Gyn Onc 1996; 62: 282-291.
17. Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403-413.
18. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
19. Tanaka M, Suda T, Haze K, et al. Fas Ligand in human serum. Nature Med 1996; 2: 317-322.
20. Skilling JS, Squatrito RC, Connor JP, Niemann T, Buller RE. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gyn Onc 1996; 60: 72-80.
21. Ephraim JF, McKenna KA, Bedi A. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32. Cancer Res 1997; 57: 2550-2554.
22. Armstrong RC, Aja T, Xiang J, et al. Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 1996; 271: 16850-16855.
23. Cai Z, Stancou R, Korner M, Chouaib S. Impairment of Fas antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumour cells. Int J Cancer 1996; 68: 535-546.
24. Zinkewich-Peotti K, Andrews PA. Loss of cis-diamminedichloroplatinum (II) resistance in human ovarian carcinoma cells selected for Rhodamine 123 resistance. Cancer Res 1992; 52: 1902-1906.
25. Mamenta E, Poma E, Kaufmann W, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1994; 54: 3500-3505.
26. Morimoto H, Yonehara S, Bonavida B. Overcoming tumour necrosis factor and drug resistance of human tumour cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 1993; 53: 2591-2596.
27. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1998; 4: 31-36.
28. Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997; 89: 1067-1076.
29. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble from of human Fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129-1135.
30. Delmastro DA, Li J, Vaisman A, Solle M, Chaney SG. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Cancer Chemo Pharm, 1997; 39: 245-253.
31. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032-3040.
32. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997; 16: 6914-6925.
33. Rensing-Ehl A, Frei K, Flury R, et al. Local Fas/APO-1 (CD95) ligand-mediated tumour cell killing in vivo. Euro J Immun 1995; 25: 2253-2258.